DK200501350A - Use of long-acting growth hormone compositions - Google Patents

Use of long-acting growth hormone compositions Download PDF

Info

Publication number
DK200501350A
DK200501350A DK200501350A DKPA200501350A DK200501350A DK 200501350 A DK200501350 A DK 200501350A DK 200501350 A DK200501350 A DK 200501350A DK PA200501350 A DKPA200501350 A DK PA200501350A DK 200501350 A DK200501350 A DK 200501350A
Authority
DK
Denmark
Prior art keywords
growth hormone
patients
apcd
long
acting growth
Prior art date
Application number
DK200501350A
Other languages
Danish (da)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK200501350A priority Critical patent/DK200501350A/en
Publication of DK200501350A publication Critical patent/DK200501350A/en

Links

Description

CLAIMS 1. A method for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV-infection in children receiving HAART treatment (HIVfHALS children); hypochondroplasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavi-cula, matacarpea, matatareea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery in e.g, hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g, from tibia or 1st toe; patients after graft implantation; articular cartilage degeneration in knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutritions! associated cardiovascular disease In APCD; reversal of cachexia in APCD; cancer In APCD; chronic abstractive pulmooal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome In APCD; impaired liver function; males with Htv infections; short bowel syndrome; male infertility; patients after major elective surgery, aloohol/dmg detoxification or neurological trauma; osteo-arthritis; or traumatically damaged cartilage, the method composing administering to a patient in need thereof an effective amount of a long-acting growth hormone composition. 2. A method for the acceleration of the healing of muscle tissue, nervous tissue or wounds; the acceleration or improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue, the method comprising administration to a patient In need thereof an effective amount of a long-acting growth hormone composition. 3. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance. 4. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation, 5. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance formulated in a sustained release formulation. 6. The use of a long-acting growth hormone composition in the manufacture of a medicament for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV-infection in children receiving HAART treatment (HIV/HALS children); hypochondrapiasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavicula, mata-carpea, matatarsea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery In e.g. hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g. from tibia or 1st toe: patients after graft Implantation; articular cartilage degeneration In knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutritions! associated cardiovascular disease in APCD; reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome in APCD; impaired liver function; males with HIV infections; short bowel syndrome; male infertility; patients after major elective surgery, a!coho|/drug detoxification or neurological trauma; osteo-arthritjs; or traumatically damaged cartilage. 7. The use of a long-acting growth hormone composition in the manufacture of a medicament for the healing of muscle tissue, nervous tissue or wounds; the acceleration ex' improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue. 8. The use according to daim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance. 9. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation. 10. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance formulated in a sustained release formulation,CLAIMS 1. A method for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV infection in children receiving HAART treatment (HIVfHALS children); hypochondroplasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavi-cula, matacarpea, matatareea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery in e.g, hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g, from tibia or 1st toe; patients after graft implantation; articular cartilage degeneration in knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutrition! associated cardiovascular disease In APCD; reversal of cachexia in APCD; cancer In APCD; chronic abstractive pulmonary disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome In APCD; impaired liver function; males with Htv infections; short bowel syndrome; male infertility; patients after major elective surgery, aloohol / dmg detoxification or neurological trauma; osteoarthritis; or traumatically damaged cartilage, the method composing administering to a patient in need thereof an effective amount of a long-acting growth hormone composition. 2. A method for the acceleration of the healing of muscle tissue, nervous tissue or wounds; the acceleration or improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue, the method comprising administration to a patient In need thereof an effective amount of a long-acting growth hormone composition. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance. 4. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation, 5. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance formulated in a sustained release formulation. 6. The use of a long-acting growth hormone composition in the manufacture of a medicament for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV infection in children receiving HAART treatment (HIV / HALS children); hypochondrapiasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavicula, mata-carpea, matatarsea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery In e.g. hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g. from tibia or 1st toe: patients after graft Implantation; articular cartilage degeneration In knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutrition! associated cardiovascular disease in APCD; reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonary disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome in APCD; impaired liver function; males with HIV infections; short bowel syndrome; male infertility; patients after major elective surgery, a! coho | / drug detoxification or neurological trauma; osteoarthritis; or traumatically damaged cartilage. 7. The use of a long-acting growth hormone composition in the manufacture of a medicament for the healing of muscle tissue, nervous tissue or wounds; the acceleration ex 'improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue. 8. The use according to daim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance. 9. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation. 10. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance formulated in a sustained release formulation,

DK200501350A 2005-09-27 2005-09-27 Use of long-acting growth hormone compositions DK200501350A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200501350A DK200501350A (en) 2005-09-27 2005-09-27 Use of long-acting growth hormone compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK200501350A DK200501350A (en) 2005-09-27 2005-09-27 Use of long-acting growth hormone compositions

Publications (1)

Publication Number Publication Date
DK200501350A true DK200501350A (en) 2005-09-27

Family

ID=35198151

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200501350A DK200501350A (en) 2005-09-27 2005-09-27 Use of long-acting growth hormone compositions

Country Status (1)

Country Link
DK (1) DK200501350A (en)

Similar Documents

Publication Publication Date Title
McELFRESH et al. Femoral and pelvic fractures after total hip arthroplasty
Bach et al. Plates versus external fixation in severe open tibial shaft fractures: a randomized trial
HRP20161040T1 (en) Pegylated recombinant human growth hormone compounds
Somayaji et al. Knee arthrodesis—a review
Eftekhar Total knee-replacement arthroplasty. Results with the intramedullary adjustable total knee prosthesis.
RU2008105545A (en) LIQUID DRUGS OF PEGLIATED GROWTH HORMONE
West et al. Total talus replacement: case series and literature review
Park et al. Total ankle arthroplasty
Hussain Metallic 3D printed total talus replacement: a case study
Johnsson et al. Function following mega total hip arthroplasty compared with conventional total hip arthroplasty and healthy matched controls
CARMICHAEL et al. Total knee arthroplasty in juvenile rheumatoid arthritis: a seven-year follow-up study
Scheerlinck et al. The femoral supracondylar nail: preliminary experience
Jackson et al. Unicompartmental knee arthroplasty
DK200501350A (en) Use of long-acting growth hormone compositions
Bhan et al. Bipolar hip arthroplasty in ankylosing spondylitis
RU2711977C1 (en) Method of knee joint arthrodesis with deep periendoprosthetic infection using intramedullary reinforced antibacterial cement implant
TYLMAN et al. Long-term results of functional treatment in intraarticular knee fractures and multifragment fractures of the shaft of femurs
Hašpl et al. Arthroplasty after war injuries to major joints
Mazur et al. Ankle arthrodesis in children.
RU2236190C2 (en) Method for treating aseptic necrosis of internal femoral condyle
Ядав et al. BIOMECHANICAL PECULIARITIES OF PLATE OSTEOSYNTHESIS FOR FRACTURES OF UPPER AND LOWER EXTREMITIES
Andreani et al. Post-Surgical Rehabilitation Management after Megaprosthesis Arthroplasty of Lower Limb
David Lin Orthopedic Rehabilitation
Gosselin et al. Adult Reconstruction
RU2128478C1 (en) Method for treating deforming arthrosis of knee joint

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment